Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin subunit gamma-1 (HBG1) and its paralog gamma-2 (HBG2) are the protein components of fetal hemoglobin (HbF), the primary oxygen carrier during fetal development. HbF possesses a higher affinity for oxygen than adult hemoglobin (HbA), facilitating the extraction of oxygen from maternal circulation across the placenta. Shortly after birth, a developmental switch occurs where HbF production is silenced and replaced by adult hemoglobin, a process regulated by repressors such as BCL11A. In patients with hemoglobinopathies like sickle cell disease or beta-thalassemia, reactivating the expression of these fetal hemoglobin genes can compensate for the lack of functional adult beta-globin. Modern therapeutic strategies, including CRISPR-based gene editing of the BCL11A enhancer or direct gene addition of modified gamma-globin sequences, aim to induce high levels of HbF to prevent the polymerization of sickle hemoglobin and improve erythropoiesis.
Induction of fetal hemoglobin expression via BCL11A inhibition or direct gene addition
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin subunit gamma-1 (HBG1) (HBG1).